Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 1997, for Cheung Laboratories, Inc. (Note: The request metadata listed "Imunon, Inc.", but the filing text identifies the registrant as Cheung Laboratories, Inc.). The company develops minimally invasive thermotherapy devices for cancer and benign prostatic hyperplasia (BPH). During this period, the company ceased active sales of current equipment to focus resources on developing new Adaptive Phase Array (APA) technology licensed from MIT and balloon catheter technology.
Key Financial Metrics
| Metric | Q1 FY1998 (Ended Dec 31, 1997) | Q1 FY1997 (Ended Dec 31, 1996) |
|---|---|---|
| Total Revenue | $0 | $94,040 |
| Net Loss | $(857,172) | $(438,257) |
| Loss Per Share (Basic) | $(0.028) | $(0.017) |
| Operating Cash Flow | $(1,136,707) | $(268,475) |
| Cash and Equivalents (Ending) | $32,611 | $9,807 |
| Total Current Liabilities | $2,189,289 | N/A |
| Accumulated Deficit | $(16,120,696) | N/A |
Material Changes vs. Prior Period
- Revenue Collapse: Revenue dropped to zero from $94,040 in the prior year quarter due to the cessation of active sales of existing equipment.
- Expense Surge: Selling, general, and administrative (SG&A) expenses nearly doubled to $725,058 from $396,276. This increase was driven by consulting, legal fees, and a one-time compensation expense of $234,375 for stock issued to Spencer Volk.
- R&D Increase: Research and development expenses more than doubled to $102,844 from $42,234 to fund new technology enhancements.
- Debt Reduction: Notes payable (other) decreased significantly from $1,369,800 to $498,000, reflecting repayments and conversions to equity.
- Share Count Growth: Outstanding shares increased from 29,095,333 to 32,760,674 due to stock issuances for cash and debt conversions.
Outlook, Risks, and Management Commentary
- Liquidity Crisis: Management states that existing capital resources are not adequate to fund operations for the next twelve months. The company is dependent on raising additional capital to continue development and seek FDA approval.
- Future Revenue: No revenue is expected from new technologies until they are developed and approved by regulatory agencies. Future revenue is anticipated from treatments and disposable kits.
- Defaults: The company disclosed a default on a $220,000 loan from the George T. Horton Trust. As of February 13, 1998, $40,000 principal plus accrued interest remained unpaid, with payment scheduled for the second fiscal quarter.
- Subsequent Event: $498,000 of notes payable and related interest were converted into 1,356,106 shares of common stock on or before February 2, 1998.
- Risks: If adequate funding is not secured, the company may be forced to delay, scale back, or eliminate operations, or relinquish rights to its technologies.
Investor Verification Checklist
- Verify the company's ability to secure immediate financing given the explicit statement that current cash ($32,611) is insufficient for 12 months of operations.
- Confirm the status of the defaulted loan to the George T. Horton Trust and whether the scheduled payment was made.
- Review the timeline for FDA approval of the new APA and balloon catheter technologies, as revenue is contingent on this.
- Assess the dilution impact of recent and potential future equity issuances required to fund operations.
- Validate the valuation and commercial viability of the MIT-licensed APA technology, which is now the core of the business strategy.